Additional Study Information: This study is for patients with prostate cancer and that require treatment because their disease is now growing. The purpose of this study is to see whether immunotherapy with nivolumab added to degarelix or nivolumab and BMS-986253 added to degarelix is safe and can decrease the chance that the cancer will come back. Degarelix is a standard of care drug used for the treatment of prostate cancer that works by suppressing your testosterone. Approximately 60 individuals will be asked to participate in this study.